vs

Side-by-side financial comparison of BIOCRYST PHARMACEUTICALS INC (BCRX) and HighPeak Energy, Inc. (HPK). Click either name above to swap in a different company.

HighPeak Energy, Inc. is the larger business by last-quarter revenue ($216.6M vs $156.4M, roughly 1.4× BIOCRYST PHARMACEUTICALS INC). On growth, BIOCRYST PHARMACEUTICALS INC posted the faster year-over-year revenue change (7.5% vs -23.3%). Over the past eight quarters, BIOCRYST PHARMACEUTICALS INC's revenue compounded faster (19.6% CAGR vs -13.2%).

BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China.

Duke Energy Corporation is an American electric power and natural gas holding company headquartered in Charlotte, North Carolina. The company serves over 7 million customers in the eastern United States. In 2024 it ranked as the 141st largest company in the United States – its highest-ever placement on the Fortune 500 list.

BCRX vs HPK — Head-to-Head

Bigger by revenue
HPK
HPK
1.4× larger
HPK
$216.6M
$156.4M
BCRX
Growing faster (revenue YoY)
BCRX
BCRX
+30.8% gap
BCRX
7.5%
-23.3%
HPK
Faster 2-yr revenue CAGR
BCRX
BCRX
Annualised
BCRX
19.6%
-13.2%
HPK

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
BCRX
BCRX
HPK
HPK
Revenue
$156.4M
$216.6M
Net Profit
$-25.2M
Gross Margin
Operating Margin
13.6%
-7.6%
Net Margin
-11.6%
Revenue YoY
7.5%
-23.3%
Net Profit YoY
-380.7%
EPS (diluted)
$0.00
$-0.16

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BCRX
BCRX
HPK
HPK
Q1 26
$156.4M
Q4 25
$406.6M
$216.6M
Q3 25
$159.4M
$188.9M
Q2 25
$163.4M
$200.4M
Q1 25
$145.5M
$257.4M
Q4 24
$131.5M
$282.6M
Q3 24
$117.1M
$271.6M
Q2 24
$109.3M
$275.3M
Net Profit
BCRX
BCRX
HPK
HPK
Q1 26
Q4 25
$245.8M
$-25.2M
Q3 25
$12.9M
$-18.3M
Q2 25
$5.1M
$26.2M
Q1 25
$32.0K
$36.3M
Q4 24
$-26.8M
$9.0M
Q3 24
$-14.0M
$49.9M
Q2 24
$-12.7M
$29.7M
Gross Margin
BCRX
BCRX
HPK
HPK
Q1 26
Q4 25
97.7%
Q3 25
98.6%
Q2 25
98.3%
Q1 25
96.9%
Q4 24
95.4%
Q3 24
97.3%
Q2 24
98.4%
Operating Margin
BCRX
BCRX
HPK
HPK
Q1 26
13.6%
Q4 25
64.0%
-7.6%
Q3 25
18.6%
17.3%
Q2 25
18.2%
21.7%
Q1 25
14.6%
35.1%
Q4 24
-3.4%
26.1%
Q3 24
6.6%
27.0%
Q2 24
8.0%
31.7%
Net Margin
BCRX
BCRX
HPK
HPK
Q1 26
Q4 25
60.5%
-11.6%
Q3 25
8.1%
-9.7%
Q2 25
3.1%
13.1%
Q1 25
0.0%
14.1%
Q4 24
-20.4%
3.2%
Q3 24
-12.0%
18.4%
Q2 24
-11.6%
10.8%
EPS (diluted)
BCRX
BCRX
HPK
HPK
Q1 26
$0.00
Q4 25
$1.13
$-0.16
Q3 25
$0.06
$-0.15
Q2 25
$0.02
$0.19
Q1 25
$0.00
$0.26
Q4 24
$-0.13
$0.06
Q3 24
$-0.07
$0.35
Q2 24
$-0.06
$0.21

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BCRX
BCRX
HPK
HPK
Cash + ST InvestmentsLiquidity on hand
$259.0M
$162.1M
Total DebtLower is stronger
$1.2B
Stockholders' EquityBook value
$1.6B
Total Assets
$465.1M
$3.2B
Debt / EquityLower = less leverage
0.75×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BCRX
BCRX
HPK
HPK
Q1 26
$259.0M
Q4 25
$274.7M
$162.1M
Q3 25
$212.9M
$164.9M
Q2 25
$260.0M
$21.9M
Q1 25
$295.1M
$51.6M
Q4 24
$320.9M
$86.6M
Q3 24
$96.8M
$135.6M
Q2 24
$78.4M
$157.9M
Total Debt
BCRX
BCRX
HPK
HPK
Q1 26
Q4 25
$1.2B
Q3 25
$1.2B
Q2 25
$1.0B
Q1 25
$1.0B
Q4 24
$1.0B
Q3 24
$1.1B
Q2 24
$1.1B
Stockholders' Equity
BCRX
BCRX
HPK
HPK
Q1 26
Q4 25
$-119.2M
$1.6B
Q3 25
$-387.9M
$1.6B
Q2 25
$-421.6M
$1.7B
Q1 25
$-451.9M
$1.6B
Q4 24
$-475.9M
$1.6B
Q3 24
$-468.6M
$1.6B
Q2 24
$-475.6M
$1.6B
Total Assets
BCRX
BCRX
HPK
HPK
Q1 26
$465.1M
Q4 25
$514.2M
$3.2B
Q3 25
$446.4M
$3.2B
Q2 25
$457.2M
$3.1B
Q1 25
$480.0M
$3.1B
Q4 24
$490.4M
$3.1B
Q3 24
$491.3M
$3.1B
Q2 24
$472.4M
$3.1B
Debt / Equity
BCRX
BCRX
HPK
HPK
Q1 26
Q4 25
0.75×
Q3 25
0.73×
Q2 25
0.62×
Q1 25
0.63×
Q4 24
0.65×
Q3 24
0.67×
Q2 24
0.70×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BCRX
BCRX
HPK
HPK
Operating Cash FlowLast quarter
$93.1M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BCRX
BCRX
HPK
HPK
Q1 26
Q4 25
$292.0M
$93.1M
Q3 25
$41.6M
$120.2M
Q2 25
$41.3M
$141.2M
Q1 25
$-27.5M
$157.1M
Q4 24
$-5.2M
$139.5M
Q3 24
$8.2M
$177.1M
Q2 24
$-1.4M
$202.3M
Free Cash Flow
BCRX
BCRX
HPK
HPK
Q1 26
Q4 25
$291.2M
Q3 25
$40.3M
Q2 25
$41.1M
Q1 25
$-27.7M
Q4 24
$-5.9M
Q3 24
$8.2M
Q2 24
$-1.5M
FCF Margin
BCRX
BCRX
HPK
HPK
Q1 26
Q4 25
71.6%
Q3 25
25.3%
Q2 25
25.2%
Q1 25
-19.0%
Q4 24
-4.5%
Q3 24
7.0%
Q2 24
-1.4%
Capex Intensity
BCRX
BCRX
HPK
HPK
Q1 26
Q4 25
0.2%
Q3 25
0.8%
Q2 25
0.1%
Q1 25
0.1%
Q4 24
0.5%
Q3 24
0.1%
Q2 24
0.1%
Cash Conversion
BCRX
BCRX
HPK
HPK
Q1 26
Q4 25
1.19×
Q3 25
3.23×
Q2 25
8.12×
5.39×
Q1 25
-859.91×
4.32×
Q4 24
15.53×
Q3 24
3.55×
Q2 24
6.81×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BCRX
BCRX

ORLADEYO$148.3M95%
Other revenues$5.0M3%
License revenue$3.0M2%

HPK
HPK

Crude Oil Sales$152.1M70%
Natural Gas And NGL Sales$60.8M28%

Related Comparisons